JeanMarieTersakMD

Pediatric Hematology & Oncology • De Lancey, PA

Professor, Pediatrics, University of Pittsburgh School of Medicine

Join to view full profile

Dr. Tersak is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Tersak's full profile

Already have an account?

Office
4910 Penn Ave
De Lancey, PA 15733

Education & Training

UPMC Medical EducationFellowship, Pediatric Hematology/Oncology, 1996 - 1999
UPMC Medical EducationResidency, Pediatrics, 1993 - 1996
University of Pittsburgh School of MedicineClass of 1993

Certifications & Licensure

PA State Medical License 1994 - 2026
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma Start of enrollment: 2001 Oct 18
ACTIVE_NOT_RECRUITING
PHASE3
Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors Start of enrollment: 2004 Feb 01
Completed
Phase 1
Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma Start of enrollment: 2005 Jul 01
Terminated
Phase 2
Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma Start of enrollment: 2008 May 06
COMPLETED
PHASE3
Neuropsychological and Behavioral Testing in Younger Patients With Cancer Start of enrollment: 2009 Feb 27
ACTIVE_NOT_RECRUITING
Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors Start of enrollment: 2004 Feb 16
Completed
Childhood Cancer Survivor Study Start of enrollment: 1995 Jan 05
RECRUITING
Roles: Contact, Principal Investigator
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Start of enrollment: 2010 Nov 22
Completed
Phase 2
Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma Start of enrollment: 2011 Sep 01
Completed
Phase 1
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma Start of enrollment: 2013 Feb 12
Completed
Phase 2
Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma Start of enrollment: 2013 Jan 31
Completed
Phase 1, Phase 2
Stress Management Intervention for Mothers of Children With Cancer Start of enrollment: 2010 Sep 01
Completed
Not Applicable
Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma Start of enrollment: 2014 Aug 01
Completed
Phase 2
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies Start of enrollment: 2014 May 16
Completed
Phase 1, Phase 2
VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors Start of enrollment: 2014 Sep 01
Completed
Phase 1
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Start of enrollment: 2014 Jul 11
ACTIVE_NOT_RECRUITING
PHASE2, PHASE3
A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors Start of enrollment: 2015 Dec 11
Completed
Phase 1
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma Start of enrollment: 2019 Jul 08
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Principal Investigator
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial Start of enrollment: 2020 Oct 13
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Principal Investigator
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT Start of enrollment: 2020 Oct 19
RECRUITING
PHASE2
Roles: Principal Investigator
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Start of enrollment: 2017 Aug 08
ACTIVE_NOT_RECRUITING
PHASE3
Roles: Principal Investigator
A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects Start of enrollment: 2019 Oct 21
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma Start of enrollment: 2014 Aug 08
ACTIVE_NOT_RECRUITING
PHASE3
Roles: Principal Investigator
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) Start of enrollment: 2018 Apr 17
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Principal Investigator
Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors Start of enrollment: 2017 Dec 06
COMPLETED
Roles: Principal Investigator
Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer Start of enrollment: 2017 Nov 29
ACTIVE_NOT_RECRUITING
PHASE3
Roles: Principal Investigator
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Start of enrollment: 2017 Jul 31
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Principal Investigator
Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors, the StepByStep Study Start of enrollment: 2020 Dec 07
ACTIVE_NOT_RECRUITING
PHASE3
Roles: Principal Investigator
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations Start of enrollment: 2020 Jul 21
ACTIVE_NOT_RECRUITING
PHASE3
Roles: Principal Investigator
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) Start of enrollment: 2020 Jul 20
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Principal Investigator
Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia Start of enrollment: 2019 Nov 08
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Principal Investigator
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma Start of enrollment: 2019 Aug 29
ACTIVE_NOT_RECRUITING
PHASE3
Roles: Principal Investigator
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma Start of enrollment: 2019 Aug 29
ACTIVE_NOT_RECRUITING
PHASE3
Roles: Principal Investigator
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Start of enrollment: 2017 Nov 28
COMPLETED
PHASE2
Roles: Principal Investigator
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) Start of enrollment: 2018 May 14
ACTIVE_NOT_RECRUITING
PHASE3
Roles: Principal Investigator
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors Start of enrollment: 2017 May 25
RECRUITING
PHASE3
Roles: Principal Investigator
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial Start of enrollment: 2021 May 03
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Principal Investigator
Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia Start of enrollment: 2018 Sep 09
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Principal Investigator
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) Start of enrollment: 2017 Aug 23
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Principal Investigator
A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery Start of enrollment: 2020 Oct 07
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Principal Investigator
Project: Every Child for Younger Patients With Cancer Start of enrollment: 2015 Nov 03
RECRUITING
Roles: Principal Investigator
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma Start of enrollment: 2022 Apr 01
RECRUITING
PHASE3
Roles: Principal Investigator
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma Start of enrollment: 2022 Aug 04
RECRUITING
PHASE3
Roles: Principal Investigator
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma Start of enrollment: 2021 Sep 14
ACTIVE_NOT_RECRUITING
PHASE3
Roles: Principal Investigator
Evaluation of Immunologic Response Following COVID-19 Vaccination in Children, Adolescents, and Young Adults With Cancer Start of enrollment: 2022 Apr 08
RECRUITING
Roles: Principal Investigator
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab Start of enrollment: 2023 May 11
RECRUITING
PHASE3
Roles: Principal Investigator
A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia Start of enrollment: 2023 Nov 30
RECRUITING
Roles: Principal Investigator
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma Start of enrollment: 2023 Mar 03
SUSPENDED
PHASE2, PHASE3
Roles: Principal Investigator
A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma Start of enrollment: 2023 Aug 18
RECRUITING
Roles: Principal Investigator
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma Start of enrollment: 2024 Apr 19
RECRUITING
PHASE3
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

2 citations
Abnormal Global Longitudinal Strain During Anthracycline Treatment Predicts Future Cardiotoxicity in Children.
Megan Gunsaulus, Tarek Alsaied, Jean M Tersak, Erika Friehling, Kirsten Rose-Felker
Pediatric Cardiology. 2024-12-01
1 citations
"Pediatrician's Approach to Recognizing Neuroblastoma With Opsoclonus-Myoclonus-Ataxia Syndrome".
Julia E Segal, A Kim Ritchey, Jean Tersak, Kavita Thakkar, Sanjay Lambore
Clinical Pediatrics. 2023-09-01
2 citations
A chronic eyelid lesion in a child: multi-disciplinary approach to diagnosis, treatment and management of a highly atypical histiocytic lesion.
Archana Ramgopal, Julia Segal, Sabrina Mukhtar, Jenny Y. Yu, Jennifer Picarsic
Pediatric Hematology and Oncology. 2021-08-11

Press Mentions

Pitt Researchers Seek Participants in Study on Fracking and Childhood CancersSeptember 20th, 2022
I Survived Childhood Cancer. Now What?September 9th, 2022
I Survived Childhood Cancer. Now What? -News ForestAugust 20th, 2022
Join now to see all

JeanMarieTersakMD

Dr. Tersak is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Viewing the full profile is available to verified healthcare professionals only.